Maximum Dose of Midodrine
The maximum dose of midodrine is 30 mg per day, typically administered as 10 mg three times daily, with individual doses not exceeding 20 mg and dosing intervals of at least 3-4 hours. 1
FDA-Approved Dosing Parameters
The FDA drug label establishes clear dosing boundaries for midodrine 1:
- Standard maximum daily dose: 30 mg/day (10 mg three times daily)
- Maximum single dose: 20 mg (though this carries a 45% risk of severe supine hypertension)
- Minimum dosing interval: 3 hours between doses
- Last dose timing: No later than 6 PM and at least 4 hours before bedtime to prevent supine hypertension during sleep
Practical Dosing Algorithm
Starting dose: 2.5-10 mg three times daily 1
Titration strategy:
- Increase gradually based on symptom response and blood pressure monitoring
- Standard therapeutic dose: 10 mg three times daily at approximately 4-hour intervals 1
- Suggested timing: upon arising, midday, and late afternoon (before 6 PM)
Special populations requiring dose reduction:
- Renal impairment: Start at 2.5 mg doses and titrate cautiously 1
- Hemodialysis patients: Midodrine is removed by dialysis; timing adjustments needed 1
Critical Safety Considerations
Supine hypertension is the dose-limiting adverse effect:
- Occurs in approximately 45% of patients at 20 mg single doses 1
- Risk increases substantially above 10 mg per dose
- Requires regular monitoring of both supine and standing blood pressures 1
Mandatory monitoring:
- Discontinue if supine blood pressure increases excessively
- Continue only if patients demonstrate symptomatic improvement 1
- Monitor for pilomotor reactions, urinary retention, and supine hypertension 2
Evidence Supporting Maximum Dose
The 30 mg/day maximum is supported by multiple lines of evidence:
Guideline recommendations: The Canadian Cardiovascular Society recommends midodrine 2.5-15 mg every 4 hours up to 3 times per day for POTS, which aligns with the 30-45 mg/day range 3. However, the FDA label's 30 mg/day limit takes precedence for safety.
Clinical trial data: Dose-response studies demonstrate that 10 mg doses provide optimal efficacy with acceptable safety 4. The 10 mg dose increased standing systolic blood pressure by 22 mmHg (28% increase) with manageable side effects 5. Higher doses (20 mg) showed increased efficacy but unacceptable rates of supine hypertension 1, 4.
Real-world experience: Transplant patients have tolerated up to 30 mg/day with careful monitoring, but this represents the upper safety boundary 6.
Pharmacokinetic Rationale
The active metabolite desglymidodrine has a half-life of 3-4 hours 1, which supports:
- Dosing intervals of 3-4 hours minimum
- Three-times-daily administration pattern
- Avoidance of evening doses to prevent nocturnal supine hypertension
The 30 mg/day maximum represents the established safety threshold beyond which systematic safety data are lacking and supine hypertension risk becomes prohibitive. 1